Development asset linked to Genzyme Europe in public FDA and regional records.
pharma · Hemophilia · Gaucher's disease type I; Gaucher's disease type III
Genzyme Europe
Genzyme Europe B.V.
Genzyme Europe drug portfolio — 10 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
NL HQ
1981 Founded
273 Employees
EMA registrant Type
Company details
- Status
- Public
- HQ
- NL
- Founded
- 1981
- Employees
- 273
- Programs
- 5
- Drugs
- 10
- Patents
- 0
Genzyme Europe pipeline
Portfolio lens on 10 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Genzyme Europe drug portfolio — 10 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
eliglustat
Alimentary tract and metabolism (A16)Alimentary tract and metabolism (A16) compound in Genzyme Europe's portfolio. Mechanism: Ceramide glucosyltransferase inhibitor.
- Mechanism
- Ceramide glucosyltransferase inhibitor
-
human coagulation factor viii / human von willebrand factor
Blood and blood forming organs (B02)Blood and blood forming organs (B02) compound in Genzyme Europe's portfolio.
-
imiglucerase
Alimentary tract and metabolism (A16)US regulatory status: approved. Molecular target: Glucocerebroside.
- Target
- Glucocerebroside
- Mechanism
- Glucocerebroside hydrolytic enzyme
-
Development asset linked to Genzyme Europe in public FDA and regional records.
-
Development asset linked to Genzyme Europe in public FDA and regional records.
-
mannitol
Respiratory system (R05)US regulatory status: approved. Mechanism: Unknown.
- Mechanism
- Unknown
-
Development asset linked to Genzyme Europe in public FDA and regional records.
-
Development asset linked to Genzyme Europe in public FDA and regional records.
-
Development asset linked to Genzyme Europe in public FDA and regional records. Molecular target: Tyrosine-protein kinase BTK.
- Target
- Tyrosine-protein kinase BTK
- Mechanism
- Tyrosine-protein kinase BTK inhibitor